cas 5775-89-3|| where to buy Ethyl 4-Bromo-1,3-dimethyl-1H-pyrazole-5-carboxylate

Название продукции:Ethyl 4-Bromo-1,3-dimethyl-1H-pyrazole-5-carboxylate

IUPAC Name:ethyl 4-bromo-1,3-dimethyl-1H-pyrazole-5-carboxylate

Упаковочная единица	Доступно для заказа	Цена ($)	Количество
CM313111-5g	in stock	ƱƋȌ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 5775-89-3 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:5775-89-3; Молекулярная формула:C8H11BrN2O2; Точка плавления:-; Smiles-код:O=C(C1=C(Br)C(C)=NN1C)OCC; Плотность:

: Номер в каталоге:CM313111; Молекулярная масса:247.09; Точка кипения:; Номер Mdl:MFCD02253803; Хранение:

: Pyrazoles; Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.; Pyrazone; Custom pyrazone for customers from all over the world are our main business.

: Lorlatinib; Pfizer announced longer-term follow-up results of the Phase 3 CROWN study at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. This study aims to evaluate the efficacy and safety of the third-generation anaplastic lymphoma kinase (ALK) inhibitor LORBRENA® (lorlatinib, available in Europe under the brand name LORVIQUA®) versus XALKORI® (crizotinib) in people with previously untreated, anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). The analysis showed that compared with the first-generation ALK inhibitors, the risk of disease progression or death in patients treated with lorlatinib continued to decrease by 81%, and the risk of brain metastasis progression was reduced by 94%.